Safety and efficacy of an orally active selective endothelin—A receptor antagonist in moderate-severe human chronic heart failure

Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252

Journal of Hypertension ◽

10.1097/00004872-200018100-00020 ◽

2000 ◽

Vol 18 (10) ◽

pp. 1507-1514 ◽

Cited By ~ 14

Author(s):

Johann Bauersachs ◽

Claude Braun ◽

Daniela Fraccarollo ◽

Julian Widdera ◽

Georg Ertl ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Chronic Heart Failure ◽

Receptor Antagonist ◽

Renal Dysfunction ◽

Endothelin A Receptor ◽

Effects of Endothelin A Receptor Blockade on Endothelial Function in Patients With Chronic Heart Failure

Circulation ◽

10.1161/01.cir.103.7.981 ◽

2001 ◽

Vol 103 (7) ◽

pp. 981-986 ◽

Cited By ~ 42

Author(s):

Rudolf Berger ◽

Brigitte Stanek ◽

Martin Hülsmann ◽

Bernhard Frey ◽

Sandra Heher ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Endothelial Function ◽

Receptor Blockade ◽

Endothelin A Receptor ◽

Improvement of Postischemic Acute Renal Failure with the Novel Orally Active Endothelin-A Receptor Antagonist LU 135252 in the Rat

Journal of Cardiovascular Pharmacology ◽

10.1097/00005344-199807000-00013 ◽

1998 ◽

Vol 32 (1) ◽

pp. 80-86 ◽

Cited By ~ 38

Author(s):

Rainer Birck ◽

Thomas Knoll ◽

Claude Braun ◽

Michael Kirchengast ◽

Klaus Münter ◽

...

Keyword(s):

Renal Failure ◽

Acute Renal Failure ◽

Receptor Antagonist ◽

The Novel ◽

Endothelin A Receptor ◽

Endothelin A ◽

7013 Phase II trial of the specific endothelin A receptor antagonist zibotentan (ZD4054) in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastases: final analysis of safety and efficacy

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71391-6 ◽

2009 ◽

Vol 7 (2) ◽

pp. 410 ◽

Cited By ~ 2

Author(s):

N.D. James ◽

T. Morris ◽

D. Phung ◽

S. McIntosh ◽

N.A. Dawson

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Receptor Antagonist ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Safety And Efficacy ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Resistant Prostate Cancer

1123-183 Sustained hemodynamic benefit in patients with pulmonary arterial hypertension after one-year of therapy with the selective orally-active endothelin-A receptor antagonist, sitaxsentan

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(04)92122-5 ◽

2004 ◽

Vol 43 (5) ◽

pp. A501-A502

Author(s):

David Langleben ◽

Andrew Hirsch ◽

Eileen Shalit ◽

Lyda Lesenko ◽

Robyn J Barst ◽

...

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Receptor Antagonist ◽

Endothelin A Receptor ◽

Pulmonary Arterial ◽

Endothelin A ◽

One Year ◽

Chronic Administration of an Endothelin-A Receptor Antagonist Improves Exercise Capacity in Rats with Myocardial Infarction-induced Congestive Heart Failure

Journal of Cardiovascular Pharmacology ◽

10.1097/01.fjc.0000166212.04674.8b ◽

2004 ◽

Vol 44 (Supplement 1) ◽

pp. S64-S67 ◽

Cited By ~ 11

Author(s):

Takashi Miyauchi ◽

Akira Fujimori ◽

Seiji Maeda ◽

Motoyuki Iemitsu ◽

Satoshi Sakai ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Congestive Heart Failure ◽

Receptor Antagonist ◽

Exercise Capacity ◽

Chronic Administration ◽

Endothelin A Receptor ◽

Acute Endothelin A Receptor Blockade Causes Selective Pulmonary Vasodilation in Patients With Chronic Heart Failure

Circulation ◽

10.1161/01.cir.101.25.2922 ◽

2000 ◽

Vol 101 (25) ◽

pp. 2922-2927 ◽

Cited By ~ 112

Author(s):

Michael M. Givertz ◽

Wilson S. Colucci ◽

Thierry H. LeJemtel ◽

Stephen S. Gottlieb ◽

Joshua M. Hare ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Receptor Blockade ◽

Pulmonary Vasodilation ◽

Endothelin A Receptor ◽

Endothelin A ◽

Selective Pulmonary Vasodilation

Long-Term Survival and Hemodynamics After Endothelin-A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition in Rats With Chronic Heart Failure

Circulation ◽

10.1161/01.cir.0000027138.07524.38 ◽

2002 ◽

Vol 106 (9) ◽

pp. 1159-1164 ◽

Cited By ~ 35

Author(s):

Paul Mulder ◽

Houssaine Boujedaini ◽

Vincent Richard ◽

Jean-Paul Henry ◽

Sylvanie Renet ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Angiotensin Converting Enzyme ◽

Angiotensin Converting Enzyme Inhibition ◽

Converting Enzyme ◽

Term Survival ◽

Endothelin A Receptor ◽

Converting Enzyme Inhibition ◽

Pharmacologic Characterization of S-1255, a Highly Potent and Orally Active Endothelin A Receptor Antagonist

Journal of Cardiovascular Pharmacology ◽

10.1097/00005344-200104000-00014 ◽

2001 ◽

Vol 37 (4) ◽

pp. 471-482 ◽

Cited By ~ 4

Author(s):

Takanori Iwasaki ◽

Shin-ichi Mihara ◽

Toshitake Shimamura ◽

Masaru Kawakami ◽

Masao Masui ◽

...

Keyword(s):

Receptor Antagonist ◽

Endothelin A Receptor ◽

Endothelin A ◽

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,

BJU International ◽

10.1111/j.1464-410x.2010.09638.x ◽

2010 ◽

Vol 106 (7) ◽

pp. 966-973 ◽

Cited By ~ 79

Author(s):

Nicholas D. James ◽

Armelle Caty ◽

Heather Payne ◽

Michael Borre ◽

Bernard A. Zonnenberg ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Receptor Antagonist ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Safety And Efficacy ◽

Efficacy Analysis ◽

Castration Resistant ◽

Endothelin A Receptor ◽